Healthcare ❯ Pharmaceuticals

Rare Diseases

CNS Disorders Orphan Drug Designation Gene Therapy Candidates Neurological Disorders Product Launches Friedreich's Ataxia Drug Development Transthyretin Amyloidosis H3 K27M-Mutant Glioma Neuromuscular Diseases Drug Treatments Tumor Treatments Cortrophin Gel Cancer Treatments Prader-Willi Syndrome

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

The all-cash deal gives the Italian group a U.S. foothold to scale a Brain Health–focused rare-disease platform.

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

BioMarin to Acquire Amicus for $4.8 Billion in Cash